MetaCap

Eloxx Pharmaceuticals (ELOX) vs Elutia (ELUT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Eloxx Pharmaceuticals is the larger company by market cap ($43.7 million vs $40.0 million), about 1.1 times the size, while Elutia is growing revenue faster (-15.0% vs -100.0%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ELOX-2.91%ELUT-7.21%
+96%+33%-30%
Jun 9, 20261 yearNov 20, 2026
ELOX-20.93%ELUT-6.24%
+59%+17%-25%
Jun 8, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ELOX versus ELUT key metrics
MetricELOXELUT
Share price$10.69$0.9001
Market cap$43.69M$39.96M
1-day change-1.75%+11.12%
YTD return—+29.88%
1-year return—+52.56%
5-year return—-82.76%
P/E ratio (TTM)5.63—
EPS (TTM)$1.90$-0.68
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$12.29M
Revenue growth (YoY)-100.00%-15.03%
Net income (latest FY)$-6.00M$53.38M
Gross margin—53.66%
Operating margin—-218.91%
Net margin—434.23%
52-week high$23.40$1.39
52-week low$8.20$0.50
Distance from 52-week high-54.32%-35.01%
Analyst consensusnonestrong_buy
Avg. price target upside+257.81%+455.49%
Average volume28.48K185.17K
Shares outstanding4.09M44.40M
Employees1025
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Elutia grew revenue faster in its latest fiscal year (-15.03% vs -100.00%).

About Eloxx Pharmaceuticals

ELOX stock →

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees

About Elutia

ELUT stock →

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 25 employees

ELOX vs ELUT FAQ

Which is bigger, Eloxx Pharmaceuticals or Elutia?

Eloxx Pharmaceuticals (ELOX) is larger, with a market capitalization of $43.69M compared with $39.96M for Elutia (ELUT).

Are Eloxx Pharmaceuticals and Elutia in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons